BioNews-TX

Category Box Plugin

Houston

Moleculin glucose decoy 2-DG

Moleculin, Working with MD Anderson, Presents New Data on Glucose Decoy, Potential Therapy for Malignant Gliomas

By on August 2nd, 2016 in

Moleculin Biotech recently presented new data on its glucose decoy 2-DG, known as WP1122, during a scientific session at the 28th Annual International Carbohydrate Symposium in New Orleans. Some of Moleculin’s anti-cancer drug candidates are developed based on discoveries made at MD Anderson Cancer Center in Houston. Moleculin attended the symposium on July 17, where it announced […]

Read more...
Zika virus interview

On Zika Virus, Dr. Peter Hotez Thinks “Haiti Is Going to Get Decimated;” Worried About “Some of the Historic Wards of Houston”

By on February 3rd, 2016 in

On Feb. 1, the World Health Organization (WHO) convened the first meeting of the International Health Regulations Emergency Committee on Zika virus, in which they assessed the severity of the global health risks that are associated with the “explosive spread” of the Zika virus throughout Latin America and the Caribbean. Due to the connection between […]

Read more...
Cancer research

Launch of Codiak BioSciences for the Development of Exosome-based Therapeutic and Diagnostic Products

By on November 30th, 2015 in

The launch of Codiak BioSciences, Inc. was recently announced, securing an $80-plus million Series A and B financing. The collaboration between ARCH Ventures and Flagship Ventures has also completed license and sponsored research agreements with The University of Texas MD Anderson Cancer Center in Houston. Exosomes are small vesicles that leave cells and travel along […]

Read more...
neurological disorders

MD Anderson Study Points To Involvement of Epidermal Growth Factor Receptor In Colorectal Cancer Recurrence

By on November 20th, 2015 in

A new study titled “PRMT1-mediated methylation of the EGF receptor regulates signalling and cetuximab response” may help explain why the human body sometimes becomes resistant to therapy with Cetuximab (Erbitux®), a monoclonal antibody therapy that inhibits the epidermal growth factor receptor (EGFR), a key therapy used in the treatment of metastatic colorectal cancer. When individuals become […]

Read more...

Dallas

Reata Pharmaceuticals IPOs, with Earnings to Support Clinical Development of Promising Therapeutics

By on May 26th, 2016 in

Reata Pharmaceuticals offered shares to the public yesterday in a much anticipated IPO with an initial offering of 5.5 million Class A common shares at an opening per-share price of $11. The company, headquartered in Irving, Texas, was seeking to raise $52.5 million, with the May 26 start of trading on the Nasdaq Global Market under the ticket symbol […]

Read more...

UT Southwestern Researcher Receives 2016 Edith and Peter O’Donnell Award for Cancer Research on MicroRNAs

By on December 16th, 2015 in

The Academy of Medicine, Engineering and Science of Texas (TAMEST) recently selected Dr. Joshua Mendell from UT Southwestern Medical Center, as the winner of the 2016 Edith and Peter O’Donnell Award in Medicine. Dr. Mendell is a Professor of Molecular Biology at UT Southwestern Medical Center, a Howard Hughes Medical Institute investigator, member of the […]

Read more...

Annual iC3 Life Science Summit Promotes North Texas As US Life Sciences Industry’s ‘3rd Coast’

By on November 4th, 2015 in

An independent not-for-profit 501(c)(6) trade association serving and representing the life sciences industry in northern Texas, BioNorth Texas’ mission is to encourage development of a rich, biotechnology-focused ecosystem for promoting growth and success of North Texas life science companies, as well as strengthening the economy of the region’s local communities, making the region a leading […]

Read more...

Reata Pharmaceuticals To Present Promising Data on Pulmonary Arterial Hypertension Therapy at Upcoming CHEST Meeting

By on September 16th, 2015 in

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company based in Irving, Texas, recently announced that it will present encouraging data on bardoxolone methyl for pulmonary arterial hypertension (PAH) at the upcoming 2015 American College of Chest Physicians (CHEST) annual meeting in Montreal, Canada. PAH is a life-threatening condition characterized by the increase of blood pressure in […]

Read more...

Austin

THBD Announces New Health and Science Facility in Temple

By on September 30th, 2015 in

The Temple Health & Bioscience District (THBD) recently announced the relocation of a building to serve as a new office and laboratory that will enhance the development of early-stage biotechnology and life science companies. The 5,000-square-foot building is located at 1802 South First St. in the Temple Medical and Education District (TMED). The relocation of the THBD building is expected to […]

Read more...
BioBot 1

BioBot 1 Released At 2015 TERMIS World Congress

By on September 8th, 2015 in

Jumping from Austin, Texas to Boston, Massachusetts, BioBots is about to release BioBot 1 at the 2015 Tissue Engineering and Regenerative Medicine International Society (TERMIS) World Congress to be held September 8-11. The company has been diligently refining its 3D bioprinter technology after receiving feedback from researchers around the world in its nine-month beta partnership […]

Read more...

New Supercomputer Models Simulate Heart Valve Tissue Response To Realistic Blood Flow

By on August 25th, 2015 in

A project utilizing the supercomputer cluster The University of Texas at Austin’s Texas Advanced Computing Center (TACC) has developed new supercomputer models that come closer than ever before to faithfully simulating behavior of normal human heart valves. The focus of a study by multi-institutional team of scientists from the Institute for Computational Engineering and Sciences […]

Read more...

CPRIT Funds Recruitment of Top Scientists for Texas Academy

By on August 20th, 2015 in

The Cancer Prevention and Research Institute of Texas (CPRIT) has granted seven awards totaling $23,000,000, which will be used by different academic facilities to hire top scientists. The grants were awarded through CPRIT’s academic research program and are expected to attract seven new cancer specialists to the region, as announced by the institute in a press release. […]

Read more...

Medical Devices

FDA Approves Intragastric Balloon ORBERA by Apollo Endosurgery, Inc.

By on August 7th, 2015 in

Apollo Endosurgery, Inc., a company on the forefront of advancing and providing minimally invasive endoscopic surgical products for bariatric and gastrointestinal procedures, announced that the US Food and Drug Administration has granted final approval of the ORBERA Intragastric Balloon, a novel component of the ORBERA Managed Weight Loss System designed to help adult obese patients lose weight […]

Read more...

Frisco-Based OxySure Systems And Cardiac Science Agree On Partnership

By on July 31st, 2015 in

OxySure Systems is a Frisco, Texas-based medical device innovator of emergency oxygen solutions that are easy to use and can save lives. The company, which manufactures, designs and distributes respiratory and medical solutions based on “oxygen from powder” technology, recently announced a partnership with Cardiac Science Corporation (Cardiac Science), a market-leading manufacturer of automated external defibrillators (AEDs). Together, the new partnership will work to […]

Read more...

Luminex Corp Files for ARIES System and HSV 1 & 2 Assay FDA Clearance

By on July 17th, 2015 in

Austin-based Luminex, a biotechnology company that develops, manufactures and markets innovative biological testing technologies with applications throughout the diagnostic and life science industries, recently announced that it has submitted 510(k) applications to the US Food and Drug Administration for the company’s Aries platform and HSV 1 & 2 Assay. The Ariex platform is designed as a cartridge-based, sample-to-answer diagnostic test […]

Read more...

Alcon Receives European Approval For Intraocular Delivery System

By on July 10th, 2015 in

Alcon, a global leader in eye care and a division of Novartis with offices in Houston and Fort Worth, recently received a European CE Mark for the AcrySof® IQ Aspheric IOL with the UltraSert™ Pre-loaded Delivery System for those undergoing cataract surgery. This new delivery system brings together the control and accuracy of a device that is manually loaded with the convenience […]

Read more...

Cancer

neurological disorders

MD Anderson Study Points To Involvement of Epidermal Growth Factor Receptor In Colorectal Cancer Recurrence

By on November 20th, 2015 in

A new study titled “PRMT1-mediated methylation of the EGF receptor regulates signalling and cetuximab response” may help explain why the human body sometimes becomes resistant to therapy with Cetuximab (Erbitux®), a monoclonal antibody therapy that inhibits the epidermal growth factor receptor (EGFR), a key therapy used in the treatment of metastatic colorectal cancer. When individuals become […]

Read more...

BCM Researchers Develop Electronic Trigger That Detects and Reduces Delays in Cancer Diagnosis

By on September 2nd, 2015 in

In a recent study published in the Journal of Clinical Oncology, a team of researchers from the Baylor College of Medicine and Michael E. DeBakey Veterans Affairs Medical Center developed an electronic trigger to search for key data that is able to detect and reduce follow-up delays for patients being assessed for a diagnosis of […]

Read more...

Cardiac Beta-Blocker Medication Found to Increase Survival in Ovarian Cancer Patients

By on August 27th, 2015 in

A study recently published in the journal Cancer revealed that beta-blocker agents can increase the survival rate in ovarian cancer patients. The study was led by researchers at The University of Texas MD Anderson Cancer Center and Washington University School of Medicine, and is entitled “Clinical impact of selective and nonselective beta-blockers on survival in […]

Read more...

MD Anderson Discovers New Insights Into Tumor Progression

By on August 19th, 2015 in

Researchers have discovered that activating growth factor receptors such as epidermal growth factor receptors (EGFR) cause tumor progression in several types of cancer. University of Texas MD Anderson Cancer Center‘s Scientists have demonstrated that EGFR might be turned off thanks to a cytokine also known as MIF (macrophage migration inhibitory factor). The research team strongly believes that this finding can transform the way medicine […]

Read more...

Vaccines

Potential New Target to Attack Flu Virus Discovered As Doubt Is Cast On Tamiflu’s Effectiveness, UT Austin

By on April 11th, 2014 in

The British Medical Journal (BMJ) recently published a preliminary report on the endpoint of a five-year campaign by independent researchers of the Cochrane’s Acute Respiratory Infections Group and the BMJ that casts doubt on the effectiveness of the antiviral drug Tamiflu (oseltamivir) manufactured by the multinational pharmaceutical firm Roche. Which makes highly topical the discovery […]

Read more...

UT Austin Pitches Vaccine Research Findings To GlaxoSmithKline

By on January 9th, 2014 in

The Austin Business Journal’s Chad Swiatecki reports that University of Texas at Austin scientists and commerce specialists are hoping that a technique developed at the school to enhance vaccine effectiveness could pay in the form of licensing fees from vaccine-manufacturing pharmaceutical firms like British multinational pharmaceutical, biologics, vaccines and consumer healthcare company GlaxoSmithKline plc (GSK). […]

Read more...

Antimicrobial Resistance Caused By Over-Use And Abuse Of Antibiotics Could Set Disease Control Back A Century

By on November 26th, 2013 in

Proliferation of antibiotics and other anti-microbials in the ecosphere is resulting in serious negative consequences. First used to treat serious infections in the 1940s, antibiotics have saved millions of lives and transformed modern medicine, but during the last 70 years, bacteria have demonstrated the ability to mutate and become resistant to every antibiotic drug developed. […]

Read more...

Study Associates Media Coverage And Internet Search Activity With Increased HPV Vaccine Adverse Events Reportage

By on November 25th, 2013 in

A new study by Texas medical researchers published in the Journal of Adolescent Health (JaAH) investigates the association between print media coverage and reporting of adverse events reports attributed to the human papilloma virus vaccine Gardasil (HPV4) and the meningitis vaccine Menactra (MNQ) among United States adolescents. The study entitled “The Role of Media and […]

Read more...
© Copyright 2013 - 2017 BioNews Services, LLC
All rights reserved.
Close